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Abstract
Mitochondrial dysfunction and oxidative stress are considered central in dopaminergic neurodegeneration in Parkinson’s
disease (PD). Oxidative stress occurs when the endogenous antioxidant systems are overcome by the generation of reactive
oxygen species (ROS). A plausible source of oxidative stress, which could account for the selective degeneration of
dopaminergic neurons, is the redox chemistry of dopamine (DA) and leads to the formation of ROS and reactive dopamine-
quinones (DAQs). Superoxide dismutase 2 (SOD2) is a mitochondrial enzyme that converts superoxide radicals to molecular
oxygen and hydrogen peroxide, providing a first line of defense against ROS. We investigated the possible interplay
between DA and SOD2 in the pathogenesis of PD using enzymatic essays, site-specific mutagenesis, and optical and high-
field-cw-EPR spectroscopies. Using radioactive DA, we demonstrated that SOD2 is a target of DAQs. Exposure to micromolar
DAQ concentrations induces a loss of up to 50% of SOD2 enzymatic activity in a dose-dependent manner, which is
correlated to the concomitant formation of protein aggregates, while the coordination geometry of the active site appears
unaffected by DAQ modifications. Our findings support a model in which DAQ-mediated SOD2 inactivation increases
mitochondrial ROS production, suggesting a link between oxidative stress and mitochondrial dysfunction.
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Introduction
Parkinson disease (PD) is a multifactorial neurodegenerative
condition characterized by the progressive loss of dopaminergic
neurons in the Substantia Nigra pars compacta and by the presence of
intracellular inclusions, known as Lewy bodies, in surviving
neurons. The role of oxidative stress and mitochondrial dysfunc-
tion in the pathogenesis of PD has received widespread interest
[1]. Oxidative stress occurs when the capacity of the endogenous
antioxidant systems are overcome by the generation of reactive
oxygen species (ROS), which ultimately leads to cellular damage
and death. A possible mechanism involved in the increase of
oxidative stress, which could account for the preferential de-
generation of dopaminergic neurons in PD, involves the redox
reactions specific of dopamine (DA). Several different pathways
have been identified for the oxidation of DA [2]. These reactions
lead to both toxic ROS and dopamine-quinones (DAQs) [3]. ROS
can damage cellular components such as lipids, proteins, and
DNA [4]. The electron-deficient quinones can also react with
cellular nucleophiles, such us cysteine residues, leading to further
cytotoxicity. DAQ modifications on tyrosine hydroxylase, the rate-
limiting enzyme in DA synthesis, or parkin, whose coding
sequence PARK2 is mutated in familiar PD, have been described
in vitro and in vivo along with important inhibiting effects on protein
functions [5,6]. We recently characterized the structural modifica-
tions and functional effects induced by DAQs on DJ-1, a protein
involved in PD proposed to act as an oxidative stress sensor [7],
and on a-synuclein, a protein involved in familiar forms of PD and
the major component of Lewy bodies [8,9,10].
In the present study, we were interested in verifying a possible
involvement of mitochondrial superoxide dismutase 2 (SOD2) in
the pathogenesis of PD. ROS are produced under physiological
conditions, in particular in the mitochondrial oxidative phosphor-
ylation process, at levels that allow scavenging by endogenous
antioxidants such as superoxide dismutases, glutathione peroxi-
dase, catalase, and small molecules such as vitamins C and E and
glutathione. Among the ROS-scavenging enzymes, SODs are
often regarded as the first line of defense [11]. These proteins
convert naturally occurring superoxide radicals to molecular
oxygen and hydrogen peroxide. Three different SOD isoenzymes
that are well compartmentalized have been characterized in
humans. SOD1 is located in the cytosol as well as in the
mitochondrial intermembrane space, but it is also present in the
peroxisomes and in the nucleus of cells [12]. SOD2 is
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38026a mitochondrial manganese enzyme, which acts as the main
scavenger of superoxide anions within mitochondria [12]. SOD3 is
an extracellular protein which is expressed in specific cell types
and tissues, such as vascular smooth muscular cells, lung, and
plasma [12].
Considering its mitochondrial localization, SOD2 appears to be
the most relevant in the context of PD. Two different studies by
the same group, based on proteomic analyses of isolated rat brain
mitochondria following exposure to DAQs, suggested a direct
interaction between SOD2 and the brain mitochondria. In the first
one, by using a combination of fluorescent probes directed against
cysteine or lysine residues, the investigators demonstrated that DA
oxidation results in the loss of mitochondrial proteins, among
which SOD2 [13]. In the second study, SOD2 was identified as
one of the proteins modified by
14C-DAQs in rat brain
mitochondria [14]. Nevertheless, the molecular mechanisms of
this interaction remain largely unexplored, as well as the potential
functional effects induced by such modifications.
In our study, we analyzed the interaction between SOD2 and
DAQs in vitro. By analysis of the relevant point mutants, we
identified the protein residues modified by the DA oxidation
products. Specifically, Cys196 appears to be the SOD2 residue
involved in the reaction with the quinone species. Exposure to
DAQs induces loss of SOD2 enzymatic activity, which is
correlated to the concomitant formation of protein aggregates.
The in vitro data presented here support the hypothesis of a role for
SOD2 in the progression of PD. As with all models, this proposal
needs to be tested in relevant cellular and animal models.
Results
Interaction between SOD2 and DAQs
To assess whether DAQs could react with SOD2, the reactions
were first followed by UV-vis spectroscopy. The use of tyrosinase
(Ty) to rapidly produce DAQs offers the advantage of preventing
the formation of radical species in solution. Ty uses molecular
oxygen to catalyze two different enzymatic reactions, the
hydroxylation of monophenols to diphenols (monophenolase
activity) and the oxidation of diphenols to quinones (diphenolase
activity). Both reactions take place without the production of
radicals using molecular oxygen as cosubstrate [15]. The oxidation
of DA generates three monomeric quinone species, dopamine-o-
quinone (DQ), aminochrome (AC), and indole-5,6-quinone (IQ)
[10], which are all potentially reactive in a cellular environment.
While the spectroscopic characterization of IQ is still elusive, DA,
DQ, and AC possess characteristic UV-Vis peaks with absorption
maxima at 280 (DA), 390 (DQ) and 300/480 (AC) nm [3]. As
previously reported [3], during the Ty-mediated oxidation of DA
at physiological pH and 25uC, only AC is detectable in the optical
spectra with no evidence of the presence of DQ. This can be
explained by the basis of the high reactivity of DQ that undergoes
an intramolecular cyclization reaction with a rate constant of
,0.15 s
21 [16]. On the contrary, the rearrangement reaction
which involves AC to form 5,6-dihydroxyindole (DHI), with a rate
constant of ,10
23 s
21, is much slower, leading to accumulation of
AC [10]. In Fig. 1A, the spectra recorded after the addition of Ty
to a solution containing DA are reported; the peaks centered at
300 and 480 nm reveal the formation of AC. As already described
[10,17], light scattering increases during the reaction as a conse-
quence of the polymerization process.
It has been proved that the rate constant of the nucleophilic
addition of free cysteine or glutathione to DQ is three orders of
magnitude faster than that of the cyclization reaction, with a value
higher than 200 s
21 [16]. It follows that SOD2, with its two free
Figure 1. UV-Vis analysis of DAQs reactivity toward SOD2. To
make the graphical visualization easier, only a few selected spectra are
shown, recorded at 10 minute intervals after the addition of Ty in the
full spectra and every 4 minutes in the insets. A) DA alone, B) DA and
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Ty does not react directly with SOD2 by UV-Vis spectroscopy
(data not shown), we analyzed the reactivity of DAQs towards the
protein. Following the addition of a catalytic amount of Ty to
a solution containing SOD2 and DA in a 1:1 molar ratio, i.e.,
a substoichiometric ratio of DA to cysteine residues, the
appearance of the peak corresponding to AC, centered at
480 nm, revealed that the newly formed DQ does not react with
the protein (Fig. 1B). A comparison of the SOD2:DA mixture
experiment with the control, reported in Fig. 1A, revealed the
formation of a new peak around 420 nm that appears after AC
formation. A very similar result was obtained working with
a SOD2:DA=1:2 molar ratio (Fig. 1C). The only difference is
shown by the intensity of the new peak, which is doubled (inset). In
conclusion, the data obtained with SOD2 suggest that, while DQ
does not react with the protein, some DA-derived species,
subsequent to AC formation, do. This analysis does not allow us
to distinguish whether only one or both cysteine residues are
involved in the interaction with DAQs. Moreover, as the observed
spectral feature at 420 nm has not been assigned to a specific
molecule, also the nature of the modification induced on SOD2
after the DAQs formation remains unclear.
For this reason, to independently verify the presence of DAQs/
SOD2 adducts, the protein was incubated with DA in the presence
of Ty and the reaction products were successively analyzed by
SDS polyacrylamide gel under denaturing conditions. The gel was
developed using the redox-cycling staining technique, which
exploits the ability of quinones and related quinoid substances to
catalyze redox cycling at an alkaline pH in the presence of excess
glycine as a reductant [18]. The released superoxide reduces
nitroblue tetrazolium to the coloured dye formazan (blue-purple
colour), which allows the detection of proteins containing quino-
compounds [18]. The reactivity of SOD2 towards the oxidation
products of DA was confirmed by showing the formation of SOD2
monomeric species covalently bound to quinoid compounds
(Fig. 2A). Increasing the DA:protein molar ratio, new bands
corresponding to high molecular weight species are also visible.
To further confirm the formation of covalent bonds between
SOD2 and DAQs and to evaluate the role of each cysteine residue,
a radioactivity assay was performed on wild-type (wt) SOD2, as
well as on Cys-to-Ala mutant proteins, to easily detect the
formation of quino-complexes and make sequence assignments.
Proteins were exposed to
14C-DA in the presence of tyrosinase, in
a 1:1 protein to DA ratio. The reaction products were first
separated by SDS-PAGE (Fig. 2B) and then detected by
autoradiography (Fig. 2C). Distinct spots of radioactivity indicated
protein targets covalently modified by
14C-DAQs. The autoradio-
gram was then aligned with the corresponding SDS-PAGE gel for
DAQ-modified protein identification. Incorporation of radioac-
tivity into the spot corresponding to the wt SOD2 indicated the
formation of SOD2/DAQ covalent adducts following the gener-
ation of quinone species. Moreover, a faint band corresponding to
the formation of covalent dimeric DAQs-modified species is also
visible in addition to the spot relative to the monomer. When
SOD2 and DA were incubated in the absence of Ty, radioactivity
was still incorporated into the monomer, although to a lower
extent. This observation suggests that, while Ty is important to
allow the rapid generation of quinone species, the oxidation
SOD2 in an equimolar ratio, and C) DA and SOD2 in a molar ratio of two.
Upward arrows and downward arrows indicate, respectively, a time-
dependent increase and decrease of the spectral features.
doi:10.1371/journal.pone.0038026.g001
Figure 2. DAQs covalently modify SOD2. A) The redox-cycling
staining of SOD2 before and after the reaction with DAQs at different
molar ratios. The pink-red ponceau coloured SOD2-corresponding band
becomes purple in the presence of DAQs. B) SDS-PAGE of SOD2 and its
C-to-A mutants after the reaction with an equimolar amount of
14C-DA
in the presence of tyrosinase. In the control, the reaction between SOD2
and DA was carried out without tyrosinase. C) The autoradiogram of the
SDS-PAGE. The spots indicate the covalent incorporation of radioactiv-
ity into the protein.
doi:10.1371/journal.pone.0038026.g002
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where cytosolic Ty is most likely absent or very low [19].
The C140A mutant showed a pattern of spots analogous to the
wt protein, while the results obtained with the C196A and
C140A/C196A double mutant were very different. With these two
mutants, we did not observe radioactive spots corresponding to
monomers or dimers, while faint radioactive bands appeared at
high molecular weights. A possible explanation is that a small
amount of protein was trapped in the neuromelanin-like
aggregates, formed during the polymerization process, which
involves DAQs.
Enzymatic Activity Modulation by DAQs
Starting from the observation of a covalent bond between
DAQs and one cysteine residue of SOD2, we analyzed whether
the enzymatic activity of the protein was affected by this
interaction. To this aim, we performed an indirect assay based
on the auto-oxidation of pyrogallol, which occurs at alkaline pH
and produces superoxide anions. This method has been reported
in the literature as one of the best in terms of reproducibility,
accuracy, and simplicity [20]. The mechanism of the auto-
oxidation involves the superoxide anion as a propagating species,
which leads to the formation of purpurogallin, which can be
followed at 420 nm. When SOD2 is present, it reacts with and
removes the superoxide anions, inhibiting the auto-oxidation of
pyrogallol and the purpurogallin formation. Pyrogallol auto-
oxidation occurred also in the aqueous stock solution; to overcome
this problem, the stock solution was prepared by dissolving
pyrogallol under anaerobic conditions.
Fig. 3A shows the kinetic profiles recorded for the auto-
oxidation of pyrogallol as control and in the presence of SOD2,
before and after the reaction with DAQs at different molar ratios.
As expected, in the presence of SOD2, the kinetics of purpur-
ogallin formation was inhibited, as indicated by a decrease of the
absorbance observed. DAQ-induced SOD2 modifications caused
an increase of pyrogallol auto-oxidation with respect to the
unmodified protein, demonstrating that DAQ reaction with SOD2
results in an inhibition of its enzymatic activity. The extent of the
inhibition depends on amount of DA used in the reaction and
therefore on the fraction of modified SOD2 molecules. The
decrease of the SOD2 activity ranges from 2566% in the presence
of an equimolar amount of DAQs to 5063% with a fivefold excess
of DAQs, as summarized in table 1. To evaluate if the DAQ-
modification of C196 was sufficient to reproduce the effects
observed with the wt protein, we repeated the enzymatic assays on
the single and double Cys-to-Ala SOD2 mutants. The DAQ
concentrations used to treat the single mutants were adjusted to
keep the cysteine to DA ratio for the single mutants comparable to
the wt protein (Fig. 3B–D). The comparison of the residual
enzymatic activities after DAQ-modification of wt, C140A,
C196A and the double mutant C140A/C196A are reported in
Fig. 4. The statistically significant DAQ-dependent inhibition of
the enzymatic activity observed for the wt protein was clearly
reproduced only with the C140A mutant. On the contrary, the
activities of C196A and C140A/C196A mutants do not show
a statistically significant DAQ-dependent effect.
Effects of DAQs on the Mn(II) Active Site and on
Aggregation
As a final objective of the present study, we tried to correlate the
loss of functional activity with structural modifications induced on
the protein by DAQs. At least two possible models could explain
the loss of activity observed in our functional experiments. First,
DAQs could induce structural changes on the active site affecting
enzymatic activity. The second model relies on more drastic
structural effects induced by DAQs that promote precipitation or
the formation of high molecular weight aggregates.
To verify whether DAQs could affect the enzymatic properties
of SOD2 by modifying the active site of the protein, high-field
high-frequency electron paramagnetic resonance (HFEPR) experi-
ments were recorded on wt SOD2 and on its C140A and C196A
single mutants. It has been shown that HFEPR produce highly
resolved Mn(II) spectra from which it is possible to determine all
the spin parameters with high accuracy. HFEPR is so sensitive to
the Mn(II) electronic structure that using this technique, it is
possible to observe differences among distinct SODs even if their
crystallographic structures are virtually identical [21,22,23]. For
this reason, HFEPR is the technique of choice to investigate
whether the Mn(II) site of SOD2 is modified after reaction with
DAQs. We first analyzed the effects of the Cys-to-Ala mutations
on the metal binding site of the protein. As shown in Fig. 5A, the
HFEPR spectra of the C146A and C196A mutants are
superimposable on that of wt protein, indicating that these
mutations do not affect the structure of the active site. Figure 5B
shows the HFEPR spectrum of wt SOD2 together with those of
the protein after reaction with DAQs at 1:1 and 1:2 ratios. The
human wt SOD2 HFEPR spectrum shows the same overall shape
of previously published Mn(II) HFEPR spectra of other SODs and
closely resembles that of the Mn-SOD from E. coli, falling into the
category of the Mn-Type HFEPR spectrum [15]. After reaction
with DAQs, the HFEPR spectrum shows no relevant changes,
indicating that in the DAQ-modified protein, the Mn(II) sites have
the same structure as in the wt protein. Moreover, the resemblance
is such that structural changes at the substrate access channel may
be ruled out since it has been shown that mutations at this
position, as well as the interaction with analogues of the substrate,
have clear effects on the HFEPR spectrum [24,25]. In addition, no
evidence of spurious Mn(II) was observed in the HFEPR spectra.
Attempts of reducing any possible oxidized manganese by adding
1 mM sodium dithionite only increased the intensity of the spectra
with no other observable changes (data not shown). Similar
conclusions can be extended to the analysis of the HFEPR spectra
of the mutants recorded before and after the reaction with DAQs
at 1:1 ratio (Fig. 5C–D). Some small differences, which are visible
for example in the splitting of the central lines of C196A:DAQ-1:1,
are a consequence of a small amount of spurious aqueous Mn(II)
(less than 1%) which gives rise to a narrow six-line component
underneath the broad component of SOD2 [24]. Despite this
spurious Mn(II), the resonances positions of SOD2 were not
affected by the DAQ modification indicating that the active site
structure was conserved.
To evaluate the second model, the same samples used in the
enzymatic assays were loaded and analyzed by SDS-PAGE under
denaturing conditions (Fig. 6). Following the exposure of SOD2 to
increasing amounts of DAQs, the intensity of the bands
corresponding to the monomeric protein decreased while new
bands appeared in the gel, as already observed with the redox-
cycling staining (Fig. 2A). Densitometric quantification indicated
that the intensity loss is approximately 1566% in the presence of
an equimolar amount of DAQs to 4865% with a fivefold excess of
DAQs. Bands corresponding to SOD2 dimers appeared in the
presence of 1:1 and 1:2 SOD2:DAQ molar ratios, whose intensity
decreased at higher DAQ concentrations, while the formation of
high molecular weights aggregates was directly correlated to the
DAQ concentration. These results strongly suggest that the
apparent inhibition of SOD2 enzymatic activity could instead be
correlated to the formation of protein aggregates.
SOD2 Modification by Dopamine Quinones
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The involvement of mitochondrial dysfunction and oxidative
stressinthepathogenesisofParkinson’sdiseaseisnowwellaccepted,
as well as the role of DA and its oxidation products in promoting
oxidativestressinsidecells[11,26,27,28,29].Nevertheless,whileDA
itself could account for the preferential dopaminergic neuron
degeneration observed in PD, it is unlikely that it is responsible for
the elevated oxidative conditions found in PD patients. Even under
pathological conditions, DA concentration is expected to be low
because of its MAO-dependent degradation, the active transport
intovesiclesbyVMAT2,anditstrappinginsideneuromelanin[28].
Figure 3. Effects of DAQ-induced modification on SOD2 activity. Pyrogallol-assay performed on A) wt SOD2, B) C140A mutant, C) C196A
mutant, and D) C140A/C196A mutant.
doi:10.1371/journal.pone.0038026.g003
Table 1. The kinetic parameters measured in the pyrogallol assay and the calculated activities for SOD2, before and after the
reaction with DAQs at different molar ratios.
Slope (AU/s) N10
4 % of inhibition Activity Specific activity (U/mg) N10
2 % activity
Control 6.660.2 – – –
SOD2 2.8360.06 5764 1.3360.12 4.460.4 100613
SOD2:DAQs=1:1 3.3160.11 50614 0.9960.11 3.360.3 75610
SOD2:DAQs=1:2 3.4060.07 4864 0.9460.10 3.160.3 71610
*
SOD2:DAQs=1:3 3.6360.03 4563 0.8260.09 2.760.3 6168
1
SOD2:DAQs=1:5 3.9660.07 4063 0.6760.08 2.260.3 5068
#
*p,0.05,
1 p,0.01,
# p,0.001 relative to the SOD2 activity before the reaction with DAQs.
doi:10.1371/journal.pone.0038026.t001
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oxidation products on very specific protein targets could affect their
function and result in an amplification of the effects of DA itself.
Recently,bymeansoftwodifferentexperimentalapproaches, ithas
been shown that SOD2 is a target of DAQs in rat brain
mitochondria [13,14], supporting the idea that a DAQ-induced
decrease of the enzymatic activity of SOD2 would exacerbate
oxidative stress leading to neuronal dysfunctions and eventually to
cell death. In light of these results, the main objective of the present
workwastoestablishapossibleinterplaybetweenDAandSOD2in
the pathogenesis of PD.
The in vitro analysis of the interaction between SOD2 and the
oxidation products of DA allowed the identification of the protein
residues involved in the interaction with DAQs, emphasizing in
particular the role of cysteine 196. The functional effect of DAQ
modification is a loss of SOD2 enzymatic activity. Nevertheless,
the effects were not drastic considering that even in the presence of
a fivefold excess of DAQs, SOD2 retained approximately 50% of
unmodified protein activity. Although it is hard to speculate about
the SOD2 to DAQ molar ratio in a neuronal environment and in
particular under pathological conditions, these data are in
agreement with the progressive nature of the disease, which
usually starts at an old age and slowly progresses over several
years. Furthermore, SOD2 is required for normal biological
function of tissues, and mice lacking SOD2 die within the first 10
days of life [30], so that the complete inactivation of the protein
would have drastic effects.
The following step was to identify the structural basis of SOD2
inactivation induced by DAQ binding. Our results clearly indicate
that DAQs promote the aggregation of SOD2 but have no effect
on the coordination geometry of the Mn(II) binding site and do
not promote the release of Mn(II). The HFEPR results may have
two different interpretations: 1) in the DAQ-modified SOD2, the
active site is unaffected and the enzymatic inactivation occurs via
a different mechanism, or 2) the reaction with DAQs induce the
oxidation of manganese to Mn(III) (or higher) which cannot be
detected by HFEPR.
The neurotoxic effects of the oxidation products of DA and
their ability to bind to sulfhydryl groups on protein cysteinyl
residues were shown a long time ago by the pioneering studies
carried out in the Hastings’ group [31,32,33] and, since then,
several DAQ-modified proteins have been reported in the
literature. For example, two different in vitro studies first
demonstrated that DAQs covalently modify sulfhydryl groups of
tyrosine hydroxylase, the rate-limiting enzyme in catecholamine
biosynthesis, resulting in the formation of cysteinyl-catechols
within the enzyme and loss of its enzymatic activity [5,34]. More
recently, DAQ binding to parkin, a ubiquitine ligase involved in
autosomal recessive juvenile forms of PD [35], has been reported
in dopaminergic cells [6]. The interaction between DAQs and the
protein, which has been associated with a loss of ubiquitin ligase
activity, has been demonstrated to promote parkin aggregation.
Also in the case of a-synuclein, a protein associated to dominantly
inherited forms of PD [36], we and others have demonstrated that
DAQ interaction with the protein promotes the accumulation of
high molecular weight SDS-resistant oligomers [9,37]. In addition,
DAQ-modified a-synuclein has been demonstrated to be poorly
degradable by chaperone-mediated autophagy (CMA), and to
block degradation of other substrates [38]. Very recently, we
characterized the structural modifications induced by DAQs on
DJ-1, a protein involved in PD, proposed to act as an oxidative
stress sensor [7]. From all of these studies and in agreement with
the data presented here, it appears that DAQ modifications may
affect cell function in several ways, spanning from direct targeting
of enzymatic or redox-sensing activities to protein degradation or
protein aggregation.
One hypothesis that arises from this work is that DAQ-induced
modification of SOD2 and the resulting decrease of enzymatic
activity can amplify DA toxicity by promoting superoxide radical
accumulation and, as a consequence, neuronal damage and death.
The correlation that we propose between DAQs and SOD2 in the
pathogenesis of PD could contribute to rationalize both the
selective damage induced by DA to a dopaminergic neuronal
population and the increased oxidative stress conditions observed.
As already emphasized, the objective of the present work was to
unravel the molecular mechanism of the interaction between DA-
derived quinones and SOD2, as well as the potential functional
effects induced by such modifications. For this reason, the detailed
in vitro analysis achieved on the isolated determinants seems very
appropriate to the goal. Nevertheless, a more complex analysis in
PD-relevant cellular and animal models is required to extend the
proposed chemistry to cells.
In conclusion, if the route of inactivation of SOD2 unraveled
here, together with the previously reported adduct formation in rat
brain mitochondria, will be verified also in animal models, they
may open new therapeutic perspectives.
Materials and Methods
SOD2 Preparation and Purification
Human wild-type SOD2 cDNA was amplified by PCR using
the pCMV-SPORT6 vector (imaGenes), containing the full-length
SOD2 coding region as template, and synthetic oligonucleotides
(Sigma-Genosys), containing the NdeI and XhoI restriction sites.
After digestion with the appropriate restriction enzymes, the PCR
product was subcloned into the NdeI-XhoI linearized pET28a
expression plasmid (Novagen), which contains a poly-histidine
region followed by a thrombin cleavage site, and introduced into
the Escherichia coli BL21(DE3) strain. The C140A, C196A, and
C140A/C196A single and double mutants were generated by site-
directed mutagenesis using specific oligonucleotides. Overexpres-
Figure 4. DAQ-induced modification on C196 affects SOD2
activity. The comparison of the residual activity after DAQ-modifica-
tion indicates that the activity of wt SOD2 and the C140A mutant
decreases significantly in the presence of DAQs in a dose-dependent
manner. The activity of C196A and C140A/C196A mutants does not
show a statistically significant DAQ-dependent effect. Values are the
mean 6 SD. * p,0.05, 1 p,0.01, # p,0.001 relative to the protein
activities before the reaction with DAQs.
doi:10.1371/journal.pone.0038026.g004
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growing cells in LB medium at 37uCt oa nO D 600 of 0.6 followed
by overnight induction with 0.1 mM isopropyl b-D-thiogalacto-
pyranoside in the presence of 3.65 mM MnCl2. After sonication
and centrifugation, the soluble fraction containing SOD2 was
purified using nickel affinity chromatography on a 1 ml HiTrap
IMAC FF column (GE Healthcare). The purified proteins were
digested with thrombin protease (Amersham Pharmacia) using the
manufacturer’s protocol. After cleavage, the His-tag was separated
from the protein using a cobalt resin His-SelectH Cobalt affinity gel
(Sigma-Aldrich). The final protein contained an extra G-S-H-M
sequence at the N-terminus.
UV-Vis Spectroscopy
Spectra were recorded on a personal computer-interfaced diode
array Agilent 8453 UV-Vis spectrophotometer. Optical measure-
ments were performed at 25uC using 100 ml HELLMA quartz
cells with Suprasil windows and an optical path length of 1 cm.
The wavelength range was 190–1100 nm. In a control experi-
ment, 50 mM DA was dissolved in 50 mM Tris-HCl, pH 7.8, and
spectra were recorded for 60 min at 30 s intervals after the
addition of 3 units of mushroom tyrosinase (Ty) (Sigma-Aldrich).
Similar experiments were then performed in the presence of
50 mM SOD2 with a 1:1 or 1:2 protein:DA molar ratio.
NBT/Glycinate Redox-cycling Staining
DAQ-modified SOD2 was detected by redox-cycling staining
[18]. Briefly, the protein samples, separated by SDS-PAGE, were
transferred to nitrocellulose membranes at 50 V for 90 min at
4uC. The membrane was first stained with Ponceau S (0.1% in 5%
acetic acid) resulting in a pink-red stain of each protein present.
After washing with water, protein-bound quinonoids were
detected by immersing the membrane in a solution of 0.24 mM
NBT in 2 M potassium glycinate (pH 10.0) for 45 min in the dark
resulting in a blue-purple stain of quinoprotein bands and no
staining of other proteins. To block the staining, the membrane
was immersed in 0.1 M borate buffer, pH 10.0.
Radioactivity Assays
The reactions were performed in a final volume of 20 ml, at
25uC, in 50 mM Tris-HCl, pH 7.8, in the presence of 100 mM
protein and 100 mM DA-8-
14C (Sigma-Aldrich), containing
Figure 5. DAQ-induced modification does not affect the Mn(II) binding site of SOD2. 285 GHz HFEPR spectra of A) wt SOD2, B) C140A
mutant, C) C196A mutant, and D) C140A/C196A mutant, at 25 K before and after the reaction with DAQs. Spectra have been arbitrarily scaled for
better comparison.
doi:10.1371/journal.pone.0038026.g005
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reaction was carried out for 60 min. The reaction products (2 ml)
were separated by 13% SDS-PAGE. After soaking in NAMP100
Amplify Fluorographic Reagent (GE Healthcare Life Science), gels
were dried and detected by autoradiography.
Indirect Activity Assay
Pyrogallol solution was prepared in dark conditions because the
molecule is photosensitive. A volume of 8 ml of water and 30 mg
of pyrogallol were mixed anaerobically to prevent pyrogallol auto-
oxidation. The exact concentration of pyrogallol was then checked
by measuring the absorbance at 267 nm using a molar extinction
coefficient 1290.8 M
21 cm
21, previously determined in our
laboratory. The assay was performed in 3 ml of 50 mM Tris-
HCl, pH 8.2, in the presence of 1 mM EDTA and 1 mM catalase.
When required, SOD2 was added to the solution to a final
concentration of 45 nM. The reactions with DAQ were performed
in 100 ml of 50 mM Tris-HCl, pH 7.8, using 2.5 units of Ty, in
the presence of 40 mM of SOD2 and different protein:DA molar
ratios. After the addition of pyrogallol to a final concentration of
0.2 mM, the auto-oxidation was followed for 120 seconds by
measuring the absorbance at 420 nm with a diode array Agilent
8453 UV-visible spectrophotometer. Each measurement was re-
peated three times and data were elaborated between 60 and 120
seconds, which represents the range where the reaction is linear.
Percent inhibition was calculated as follows:
% inhibition = [(control rate-sample rate)/control rate] x 100.
An arbitrary unit is usually defined as the amount of enzyme
required to inhibit the auto-oxidation of pyrogallol by 50%. Data
were analyzed using GraphPad Prism 4 software. One-way
ANOVA followed by Tukey’s post hoc test was used to determine
whether groups were statistically different. P values ,0.05 were
considered significant.
EPR Spectroscopy
The high frequency electron paramagnetic resonance (HFEPR)
spectrometer has been described in detail elsewhere [39]. Field
calibration was based on a Mn(II)-doped MgO standard sample
(g=2.000101) [40], and the absolute error in field measurements
was 1 G (0.1 mT) or 0.0001 in g. All spectra were obtained with
10 G modulation under non-saturating conditions at 285 GHz
with 5 G resolution at 25 K. The quality of spectra was such that
they could be reliably reproduced and singly and doubly
integrated.
SDS-Page Quantification
The same samples used in the enzymatic assays were loaded and
separated by 13% SDS-PAGE under denaturing conditions. The
dried gels were analyzed with ImageJ (Rasband, W.S., ImageJ,
U.S. National Institutes of Health, Bethesda, Maryland, USA,
http://rsb.info.nih.gov/ij/) for densitometry quantification. Ex-
periments were performed in triplicate, and results are reported in
the text as mean and standard deviation.
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